Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

HPV16-E711-19 peptide vaccine DPX-E7

A therapeutic vaccine composed of a synthetic peptide consisting of amino acids 11 through 19 of the viral oncoprotein human papillomavirus (HPV) subtype 16 E7 (HPV16-E7 11-19), with potential antineoplastic and immunostimulating activities. Immunization with the DPX-E7 HPV vaccine may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the HPV16-E7 protein. HPV type 16 plays a key role in the carcinogenesis of certain cancers.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	DPX-E7 vaccine HPV16-E7 11-19 nanomer vaccine DPX-E7 HPV16-E7 11-19 vaccine
Code name:	DPX E7 DPX-E7

HPV16-E711-19 peptide vaccine DPX-E7

Search NCI's Drug Dictionary